Can-Fite Biopharma Ltd ADR (AMEX:CANF) currently has a daily average trading volume of 280.91K but it saw 349392 shares traded in last market. With a market cap of 12.54M USD, the company’s current market price of $1.20 came falling about -2.44 while comparing to the previous closing price of $1.23. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.69 and as low as $1.18. In the recent trading on the day, stock has struck highest price mark of $1.18 while lowest mark touched by it was $1.25.
Taking a look at 20-day trading activity of Can-Fite Biopharma Ltd ADR (CANF) gives us an average price of $1.4408, while its current price level is -74.41% below from 52-week high level whereas it is 1.69% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.5474 while that of 200 days or SMA-200 reads an average of $2.0608. A closer look into the stock’s movement over the week reveals that its volatility is standing at 16.61% during that period while stretching the period over a month that decreases to 9.79%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.18 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Maxim Group which initiated the stock as “Buy” in its note to investors issued on August 11, 2017, recommending a price target of $7 for it. Rodman & Renshaw issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, CANF’s stock price is moving -14.16% down while it is -26.32% when we observe its performance for the past one month. Year-to-date it is -26.15% down and over the past year, the stock is showing a downside performance of -42.31%.
The company is expected to be releasing its next quarterly report on 2024-Mar-27, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Can-Fite Biopharma Ltd ADR’s total number of outstanding shares is 4.53M with 0.00% of that held by the insiders while 1.28% of its common stock has been owned by the institutions. Stock’s beta reads 1.17.
